YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey

Clinical Trial Summary

To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients

Clinical Trial Description

A total sample size of 160 to 200 HCPs and 160 to 200 patients ;

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Advanced Melanoma

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05039801` - IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	Phase 1
Terminated	`NCT04894994` - FLX475 in Combination With Ipilimumab in Advanced Melanoma	Phase 2
Completed	`NCT01621490` - PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma	Phase 1
Recruiting	`NCT05098184` - Study on TIL for the Treatment of Advanced Melanoma	Early Phase 1
Completed	`NCT02177110` - A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Completed	`NCT00197912` - Dendritic Cell Based Therapy of Malignant Melanoma	Phase 1/Phase 2
Completed	`NCT04165967` - Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma	Phase 1
Active, not recruiting	`NCT04495257` - A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)	Phase 1
Recruiting	`NCT05968690` - Naltrexone and Propranolol Combined With Immunotherapy	Phase 1
Active, not recruiting	`NCT03200847` - Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma	Phase 1/Phase 2
Recruiting	`NCT05105100` - Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
Completed	`NCT02171286` - The Oncopanel Pilot (TOP) Study	N/A
Terminated	`NCT01453361` - Phase II FANG™ in Advanced Melanoma	Phase 2
Recruiting	`NCT05120024` - Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice
Active, not recruiting	`NCT04514484` - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Phase 1
Active, not recruiting	`NCT04951583` - Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma	Phase 2
Recruiting	`NCT06112808` - A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin	Phase 1
Recruiting	`NCT01614301` - Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma	Phase 1/Phase 2
Recruiting	`NCT04640545` - A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma	Phase 1
Active, not recruiting	`NCT03086174` - Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma	Phase 1

NCT number	NCT02224768
Study type	Observational
Source	Bristol-Myers Squibb
Contact
Status	Completed
Phase	N/A
Start date	July 2015
Completion date	November 2015